Drugs / Dazostinag
Dazostinag
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06062602 | Jul 2021 → Nov 2022 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04879849 | Sep 2021 → Apr 2024 | head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma | Takeda | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04420884 | Jul 2020 → Mar 2026 | neoplasm | Takeda | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dazostinag | “TAK-500 is a novel immune cell-directed antibody-drug conjugate (iADC) composed of TAK-202, an anti-CCR2 monoclonal antibody, conjugated to the STING agonist dazostinag...” PMID 41888610 ↗ Apr 2026 |
| Known as | Dazostinag disodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067966 ↗ |
| Known as | DAZOSTINAG SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067966 ↗ |
| Known as | TAK-676 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04879849 ↗ |
| Known as | TAK-676 sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067966 ↗ |
| Action | Activate | “TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration.” PMID 36923556 ↗ Jun 2022 |
| Modality | Small molecule | — CHEMBL6067966 ↗ |
| Route | Intravenous | “Dazostinag intravenous infusion.” NCT04420884 ↗ |